Anna Jo

Anna Jo

Auto-generated profile, based on publicly available information

Anna Jo

Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
MKMina Kim
Mina Kim
SYSoo Jin Yang
Soo Jin Yang
HKHyang Hee Kim
Hyang Hee Kim
AJAnna Jo
Anna Jo
MJMin Jhon
Min Jhon
Sung-Wan KimSung-Wan Kim
Sung-Wan Kim
Mina Kim, Soo Jin Yang, Hyang Hee Kim, Anna Jo, Min Jhon, Ju-Yeon Lee, Seung-Hyung Ryu, Jae-Min Kim, Young-Ran Kweon, Sung-Wan Kim. Clin Psychopharmacol Neurosci 2023;21:68-76. https://doi.org/10.9758/cpn.2023.21.1.68

6 June 2025 in Schizophrenia
Verified
Journal Article
Open access
PDF file
DMDaniel H. Mathalon
Daniel H. Mathalon
SNSpero Nicholas
Spero Nicholas
BRBrian J. Roach
Brian J. Roach
TBTashrif Billah
Tashrif Billah
SLSuzie Lavoie
Suzie Lavoie
GLGregory A. Light
Gregory A. Light
Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), event-related oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response, and resting EEG PSD for traditional frequency bands (eyes open/closed). Here, in an interim analysis of AMP SCZ EEG measures, we assess test-retest reliability and stability over sessions (baseline, month-2 follow-up) in CHR (n = 654) and community control (CON; n = 87) participants. Reliability was calculated as Generalizability (G)-coefficients, and changes over session were assessed with paired t-tests. G-coefficients were generally good to excellent in both groups (CHR: mean = 0.72, range = 0.49–0.85; CON: mean = 0.71, range = 0.44–0.89). Measure magnitudes significantly (p < 0.001) decreased over session (MMN, auditory and visual target P3b, visual novel P3a, 40-Hz ASSR) and/or over runs within sessions (MMN, auditory/visual novel P3a and target P3b), consistent with habituation effects. Despite these small systematic habituation effects, test-retest reliabilities of the AMP SCZ EEG-based measures are sufficiently strong to support their use in CHR studies as potential predictors of clinical outcomes, markers of illness progression, and/or target engagement or secondary outcome measures in controlled clinical trials. Watch Dr Daniel H. Mathalon discuss their work and this article: https://vimeo.com/1066564687.

28 February 2023 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
Sung-Wan KimSung-Wan Kim
Sung-Wan Kim
BLBong-Ju Lee
Bong-Ju Lee
ECEun-Jin Cheon
Eun-Jin Cheon
Seunghee WonSeunghee Won
Seunghee Won
AJAnna Jo
Anna Jo
YCYoungChul Chung
YoungChul Chung
Sung-Wan Kim, Bong-Ju Lee, Eun-Jin Cheon, Seung-Hee Won, Anna Jo, Jae-Min Kim, Young-Chul Chung. Clin Psychopharmacol Neurosci 2023;21:57-67. https://doi.org/10.9758/cpn.2023.21.1.57

27 September 2025 in International Journal of Social Psychiatry
Verified
Journal Article
Closed access
SRSeunghyong Ryu
Seunghyong Ryu
AJAnna Jo
Anna Jo
HKHoney Kim
Honey Kim
JKJu-Wan Kim
Ju-Wan Kim
BLBong Ju Lee
Bong Ju Lee
SKSung-Wan Kim
Sung-Wan Kim
Purpose: This study aimed to examine how family cohesion and adaptability are associated with mental health outcomes, including functionality, mood, stress, and well-being, in individuals with schizophrenia. Methods: A total of 225 individuals diagnosed with schizophrenia spectrum and other psychotic disorders were included in the analysis. Participants were assessed using the Family Adaptability and Cohesion Evaluation Scale (FACES-III), Positive and Negative Syndrome Scale (PANSS-6), Drug Attitude Inventory (DAI-10), Social and Occupational Functioning Assessment Scale (SOFAS), Health of the Nation Outcome Scales (HoNOS), Beck Depression Inventory (BDI-I), Perceived Stress Scale (PSS-10), Subjective Well-being under Neuroleptics Scale (SWN-20), Warwick-Edinburgh Mental Well-being Scale (WEMWBS), and Multidimensional Scale of Perceived Social Support (MSPSS). K-means clustering was performed to classify participants into distinct groups based on FACES-III scores. Results: K-means clustering, based on FACES-III scores, classified participants into high cohesion and adaptability (HC-HA; N = 139) and low cohesion and adaptability (LC-LA; N = 86) groups. No significant differences were observed in symptom severity (PANSS-6), medication adherence (DAI-10), or functionality measured by SOFAS. However, overall psychosocial functioning (HoNOS) was better in the HC-HA group. The HC-HA group exhibited lower depressive symptoms (BDI-I) and stress levels (PSS-10), as well as higher subjective well-being (SWN-20) and mental well-being (WEMWBS) compared to the LC-LA group. Perceived social support (MSPSS) was significantly higher in the HC-HA group. Conclusion: Family cohesion and adaptability are associated with improved psychosocial outcomes in individuals with schizophrenia. These findings suggest that enhancing family dynamics may support recovery and well-being.